Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Lowered by BidaskClub

Protagonist Therapeutics (NASDAQ:PTGX) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, BidAskClub reports.

Several other research firms have also recently weighed in on PTGX. Zacks Investment Research cut Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. HC Wainwright started coverage on Protagonist Therapeutics in a research report on Monday, July 8th. They set a “buy” rating and a $23.00 target price on the stock. Stifel Nicolaus upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating and upped their target price for the company from $11.00 to $17.00 in a research report on Wednesday, May 8th. Finally, ValuEngine upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, May 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $17.17.

Shares of PTGX traded down $0.21 during mid-day trading on Thursday, hitting $10.35. The company had a trading volume of 102,576 shares, compared to its average volume of 186,974. The business has a 50-day moving average of $12.29. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.02 and a current ratio of 5.02. Protagonist Therapeutics has a 1-year low of $5.49 and a 1-year high of $14.36.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Wednesday, May 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.01. Protagonist Therapeutics had a negative net margin of 209.02% and a negative return on equity of 40.78%. The business had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $2.50 million. As a group, sell-side analysts expect that Protagonist Therapeutics will post -2.07 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the stock. D. E. Shaw & Co. Inc. raised its stake in shares of Protagonist Therapeutics by 75.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 19,645 shares of the company’s stock worth $132,000 after purchasing an additional 8,450 shares during the last quarter. Bank of Montreal Can grew its position in shares of Protagonist Therapeutics by 1,675.5% in the first quarter. Bank of Montreal Can now owns 11,026 shares of the company’s stock valued at $139,000 after purchasing an additional 10,405 shares during the period. Bank of America Corp DE grew its position in shares of Protagonist Therapeutics by 94.3% in the fourth quarter. Bank of America Corp DE now owns 26,419 shares of the company’s stock valued at $178,000 after purchasing an additional 12,819 shares during the period. Northern Trust Corp grew its position in shares of Protagonist Therapeutics by 17.2% in the fourth quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock valued at $234,000 after purchasing an additional 5,084 shares during the period. Finally, Tibra Equities Europe Ltd acquired a new stake in shares of Protagonist Therapeutics in the first quarter valued at about $410,000. 64.39% of the stock is currently owned by institutional investors and hedge funds.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Further Reading: Golden Cross

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.